Study guide
3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology
USMLE Step 2 CK Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Human Development & Well-Patient Care
1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening
2 Chapter 2: Immune System & Immunologic Disorders
2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles
3 Chapter 3: Blood & Lymphoreticular System
3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders
4 Chapter 4: Behavioral Health & Psychiatric Disorders
4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology
5 Chapter 5: Nervous System & Special Senses
5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies
6 Chapter 6: Musculoskeletal System & Dermatology
6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders
7 Chapter 7: Cardiovascular System
7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease
8 Chapter 8: Respiratory System
8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases
9 Chapter 9: Gastrointestinal System
9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis
10 Chapter 10: Renal, Urinary & Reproductive Systems
10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease
11 Chapter 11: Pregnancy, Childbirth & Puerperium
11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management
12 Chapter 12: Endocrine System
12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology
13 Chapter 13: Multisystem Processes & Critical Care
13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens
14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation
14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine
15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice
15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions
3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology
Key Takeaways Explain This Topic AI
Primary hemostasis defects (platelet disorders, von Willebrand Disease) present with mucosal bleeding, petechiae, and epistaxis with prolonged Bleeding Time or PFA-100 closure time, whereas secondary hemostasis defects (coagulation factor deficiencies) present with deep tissue hematomas, hemarthroses, and delayed bleeding with prolonged PT or aPTT.
Immune Thrombocytopenia (ITP) is diagnosed by isolated thrombocytopenia (< 100,000/µL) with normal PT/aPTT and normal peripheral smear; first-line therapy for severe bleeding or platelets < 30,000/µL includes corticosteroids and intravenous immunoglobulin (IVIG).
Thrombotic Thrombocytopenic Purpura (TTP) presents with the classic pentad (Thrombocytopenia, Microangiopathic Hemolytic Anemia [schistocytes], Neurologic deficits, Renal failure, Fever) due to severe ADAMTS13 deficiency (< 10% activity); emergency therapeutic plasma exchange (TPE) must be initiated immediately without waiting for ADAMTS13 confirmation, and platelet transfusions are strictly contraindicated.
Von Willebrand Disease (vWD), the most common inherited bleeding disorder, shows abnormal ristocetin cofactor activity and reduced vWF antigen, with prolonged aPTT due to concomitant factor VIII degradation; mild bleeding is treated with desmopressin (DDAVP).
Disseminated Intravascular Coagulation (DIC) causes widespread microvascular thrombosis and consumption coagulopathy, characterized by prolonged PT/aPTT, severe thrombocytopenia, low fibrinogen (< 100-150 mg/dL), and markedly elevated D-dimer (> 500 ng/mL FEU).
Last updated: July 2026
Primary vs. Secondary Hemostasis
Evaluation of bleeding symptoms on USMLE Step 2 CK begins with distinguishing disorders of primary hemostasis (platelet plug formation) from secondary hemostasis (coagulation cascade cross-linking of fibrin).
- Feature Primary Hemostasis Defect Secondary Hemostasis Defect
- Primary Pathology Platelet deficiency or dysfunction; vWD Coagulation factor deficiency or inhibitor
Clinical Manifestations Mucosal bleeding, epistaxis, petechiae, purpura, menorrhagia Deep tissue hematomas, hemarthroses, delayed surgical bleeding
- Bleeding Time / PFA-100 Prolonged (> 8 minutes / PFA closure time > 120 s) Normal
- Prothrombin Time (PT/INR) Normal Prolonged (Extrinsic/Common pathway defects)
- Activated PTT (aPTT) Normal (except in vWD type 1/2/3) Prolonged (Intrinsic/Common pathway defects)
- Quantitative & Qualitative Platelet Disorders
- Immune Thrombocytopenia (ITP)
Autoimmune anti-GPIIb/IIIa IgG antibody-mediated platelet destruction by splenic macrophages. Diagnosed by isolated thrombocytopenia (< 100,000/µL) with normal red and white cell lines, normal PT/aPTT, and normal peripheral smear.
Acute ITP : Predominantly in children following viral infections; self-limiting within 6 months.
Chronic ITP : Predominantly in adult females (ages 20–50); rarely remits spontaneously.
Management : If asymptomatic with platelets ≥ 30,000/µL, observe. If platelets < 30,000/µL or active mucosal bleeding, initiate corticosteroids (prednisone 1 mg/kg) and IVIG . Splenectomy or TPO receptor agonists (eltrombopag, romiplostim) are reserved for refractory cases.
Qualitative Platelet Disorders
Bernard-Soulier Syndrome : Autosomal recessive deficiency of GPIb , impairing platelet adhesion to subendothelial von Willebrand factor (vWF). Smear shows abnormally large platelets (giant platelets) and severe thrombocytopenia. Ristocetin agglutination test is abnormal and does NOT correct with normal plasma.
Glanzmann Thrombasthenia : Autosomal recessive deficiency of GPIIb/IIIa , impairing platelet aggregation via fibrinogen bridging. Normal platelet count and morphology; abnormal aggregation with ADP, epinephrine, and collagen, but normal response to ristocetin .
Microangiopathic Hemolytic Anemias (MAHA)
MAHA disorders feature microvascular hyaline thrombi that shear circulating RBCs, generating schistocytes (helmet cells) on blood smear alongside microvascular ischemia.
Thrombotic Thrombocytopenic Purpura (TTP)
Caused by severe deficiency of ADAMTS13 (< 10% activity), a metalloprotease that cleaves ultra-large vWF multimers. Multi-organ microthrombi ensue. Presents with the classic pentad (recalled by FAT RN ):
F ever
A nemia (Microangiopathic Hemolytic Anemia with schistocytes, elevated LDH, indirect hyperbilirubinemia, undetectable haptoglobin)
- T hrombocytopenia (severe, often < 20,000/µL)
- R enal failure (mild to moderate)
- N eurologic deficits (confusion, seizures, focal deficits, fluctuating status)
Critical Clinical Rule : Do NOT wait for ADAMTS13 activity test results to begin treatment. Immediately initiate Therapeutic Plasma Exchange (TPE) with fresh frozen plasma. Platelet transfusions are strictly contraindicated as they fuel microvascular thrombosis.
Hemolytic Uremic Syndrome (HUS)
Driven by Shiga toxin ( E. coli O157:H7 or Shigella dysenteriae ) injuring renal glomerular endothelial cells. Predominantly affects children presenting with bloody diarrhea followed by triad : Microangiopathic Hemolytic Anemia, Severe Acute Kidney Injury, and Thrombocytopenia. Management is supportive (fluid management, dialysis); antibiotics and antimotility agents are contraindicated as they increase toxin release.
- Secondary Hemostasis & Coagulopathies
- The Coagulation Cascade & Mixing Studies
Intrinsic Pathway (measured by aPTT ): Factors XII, XI, IX, VIII.
Extrinsic Pathway (measured by PT/INR ): Factor VII and Tissue Factor.
Common Pathway (measured by PT and aPTT ): Factors X, V, II (prothrombin), and I (fibrinogen).
When a patient presents with an isolated prolonged aPTT or PT, a 1:1 Mixing Study (mixing patient plasma 1:1 with normal pooling plasma) is performed:
Correction of PT/aPTT : Indicates a Factor Deficiency (e.g., Factor VIII deficiency in Hemophilia A).
Failure to Correct : Indicates a Factor Inhibitor (e.g., Factor VIII inhibitor or Lupus Anticoagulant). [ Patient with Isolated Prolonged aPTT ]
- │
- Perform 1:1 Mixing Study
- │
- ┌───────────┴───────────┐
- ▼ ▼
- aPTT Corrects aPTT Fails to Correct
- (Factor Deficiency) (Factor Inhibitor)
- │ │
- Assay Factors Assay Inhibitor Titers
- VIII, IX, XI or Lupus Anticoagulant
- │ │
- ┌─────┴─────┐ ┌─────┴─────┐
- ▼ ▼ ▼ ▼
- Factor VIII Factor IX Factor VIII Lupus
- Deficiency Deficiency Inhibitor Anticoagulant
- (Hemophilia (Hemophilia (Bethesda (Antiphospholipid
- A) B) assay) Syndrome)
- Inherited Factor Deficiencies
Hemophilia A : X-linked recessive Factor VIII deficiency. Prolonged aPTT, normal PT. Treated with recombinant Factor VIII concentrate or emicizumab (bispecific antibody mimicking FVIIIa).
Hemophilia B (Christmas Disease) : X-linked recessive Factor IX deficiency. Treated with recombinant Factor IX.
Von Willebrand Disease (vWD) : Autosomal dominant. vWF carries Factor VIII and mediates platelet-subendothelium adhesion. Patients present with mucosal bleeding and prolonged aPTT (due to low Factor VIII levels). Diagnosed by low vWF antigen and low ristocetin cofactor activity . Mild bleeding treated with desmopressin (DDAVP) , which releases vWF from endothelial Weibel-Palade bodies.
Acquired Coagulopathies
Disseminated Intravascular Coagulation (DIC) : Uncontrolled coagulation cascade activation triggered by sepsis (gram-negative endotoxin), trauma, malignancy (APL), or obstetric catastrophes (abruptio placentae). Leads to widespread microthrombi AND severe consumption bleeding. Labs: Prolonged PT and aPTT , platelets < 50,000/µL , fibrinogen < 100 mg/dL , and d-dimer > 500 ng/mL .
Heparin-Induced Thrombocytopenia (HIT Type II) : IgG antibodies against Heparin-Platelet Factor 4 (PF4) complexes . Causes a ≥ 50% drop in platelet count starting 5–10 days after heparin exposure , accompanied by venous or arterial thrombosis. Management requires immediate cessation of all heparin (including flushes) and initiation of a non-heparin direct thrombin inhibitor ( argatroban or bivalirudin ).